Cognition Disorders
43 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| AB-1001 Gene Therapy for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active tDCS with Sternberg task for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aducanumab for cognitive dysfunction | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATTN201 Focused Ultrasound to the CMN for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Audiovisual stimulation VR system for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Buntanetap tartrate for cognitive dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cal-Mag Butyrate for cognition disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphovenous Anastomosis + Routine Treatment for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Device-only fitting for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab for cognitive dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Exablate Model 4000 Type 2 + ADUCANUMAB + LECANEMAB for cognitive dysfunction | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Facilitate tDCS + CR for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fasudil for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Focused Transcranial Ultrasound for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GENUS device (Active Settings) for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ginkgo for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High doses of Thiamine y Biotin for huntington disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| human Mesenchymal Stem Cells for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intra-striatal rAAV5-miHTT for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Lecanemab for cognitive dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| LY-2599666 for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mad for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Metformin hydrochloride for cognitive dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Moderate doses of Thiamine y Biotin for huntington disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nicotinamide Riboside (NR) for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + ADUCANUMAB for cognitive dysfunction | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + SRP-1005 for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Receive tDCS+CR for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| REPAIR Sleep for cognition disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RP902 for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sense4Safety for cognitive dysfunction | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Service-only Fitting for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium oligo-mannurarate 600mg for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium oligo-mannurarate 900mg for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Solanezumab for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Task-oriented resistance exercise for cognitive dysfunction | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tominersen for huntington disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| tributyrin for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Trontinemab for cognitive dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valacyclovir for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vericiguat for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Votoplam (blinded) for huntington disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |